Aenova Group in the news

Aenova Group expanded its automated semi-solids tube packaging capacity at its Feldkirchen site, increasing annual capacity to 50 million tubes and enhancing global traceability.

Denitsa Zapryanova, Head of Compliance at Aenova Group, attributes her structured approach and high standards to her 17-year tenure at Alvarez & Marsal.

Aenova Group appointed Alexandre Pasini as its new Chief Operating Officer, emphasizing operational excellence and strengthening its CDMO position.

Aenova Group is investing 100 million euros to expand its sterile fill and finish capabilities, warehouse, and QC lab at its Latina site, creating nearly 100 new jobs.

Aenova is significantly expanding its Killorglin facility to enhance drug delivery system development, particularly for poorly soluble drugs, creating new R&D jobs.

Aenova expands its Killorglin facility with a spray drying platform to enhance drug bioavailability and accelerate pharmaceutical development.

Aenova expanded its Killorglin site, adding 10 jobs in R&D and making it a hub for particle engineering to improve drug bioavailability.

Aenova Group's Killorglin facility is expanding, creating 10 new jobs in R&D to develop innovative drug delivery systems with government support.

Aenova invests 20 million euros in its Bad Aibling site to expand manufacturing and packaging capacities for blister products and effervescent tablets.

Aenova Group appointed Dr. Hans Engels as CEO of its US division, Swiss Caps USA, to expand its presence and lead operations at its Miami plant.

Aenova Group is moving its effervescent manufacturing from Switzerland to Germany to increase capacity and streamline logistics, adding 30 jobs.

Aenova is investing approximately •8 million to install a new gummy production line at its Romanian facility, boosting capacity to one billion gummies annually to meet rising market demand.

Kühne Holding purchased pharmaceutical contract manufacturer Aenova Group from BC Partners, with BC Partners reinvesting as a minority shareholder.

BC Partners is selling its majority stake in pharmaceutical manufacturer Aenova Group to Kuhne Holding.

Kühne Holding AG is set to acquire Aenova Group, a global pharmaceutical contract development and manufacturing organization.

Kühne Holding AG is set to acquire Aenova Group, a global pharmaceutical contract development and manufacturing organization, from BC Partners, which will retain a minority stake.

Billionaire Klaus-Michael Kühne's holding company is acquiring Bavarian contract pharmaceutical manufacturer Aenova, expanding its investment portfolio into the healthcare sector.

Aenova Group opened a new 25 million Euro production building in Regensburg to manufacture high-potency drugs, including those for cancer, meeting increased global demand.

Aenova opened a new 25 million euro facility in Regensburg to boost development and production of highly potent active pharmaceutical ingredients, including cancer drugs, with increased capacity and flexibility.

Aenova Group invested 25 million Euros to open a new production building in Regensburg for highly potent cancer drugs.